Research published in Journal of Psychoactive Drugs (page 8)

Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States

Journal of Psychoactive Drugs September 1, 2021 Alan K. Davis, Gabrielle Agin-Liebes, Megan España et al. 103 citations

Psychologists are a vital component of mental health treatment and their perceptions of psychedelic-assisted therapy are critical for future implementation. This cross-sectional quasi-experimental electronic survey study explored the attitudes about psychedelics used in treatment among 366 clinical psychologists in the United States. Participants expressed cautiously favorable attitudes toward...

DOI: 10.1080/02791072.2021.1971343

Psychedelic Knowledge and Opinions in Psychiatrists at Two Professional Conferences: An Exploratory Survey

Journal of Psychoactive Drugs August 19, 2021 Brian S. Barnett, Yvan Beaussant, Franklin King et al. 64 citations

Despite resurgent interest in psychedelic-assisted therapy, our insights into psychiatrists' knowledge and opinions about medicinal psychedelic applications are surprisingly narrow. Therefore, we anonymously surveyed psychiatrists attending psychedelic didactic presentations at two national meetings about these issues using a 26-item questionnaire. Response rate was 40.20% (106/264)....

DOI: 10.1080/02791072.2021.1957183 Addiction Legalization Exploratory research Social science

Exploring the Use of Psilocybin Therapy for Existential Distress: A Qualitative Study of Palliative Care Provider Perceptions

Journal of Psychoactive Drugs July 16, 2021 Coryn E. Mayer, Virginia Lebaron, Kimberly Acquaviva 17 citations

There is a growing body of research suggesting that palliative care patients coping with existential distress may benefit from psilocybin. However, there is a large gap regarding the perceptions of palliative care providers who may provide education, counseling services, recommendations, and/or prescriptions for psilocybin if it is decriminalized, commercialized, and/or federally rescheduled...

DOI: 10.1080/02791072.2021.1916659 Psilocybin Palliative care Distress Existentialism +5

Cognitive Behavioral Therapy, Ketamine, and Combination Treatment for Depression: Impressions of Credibility in Participants with Self-Reported Depressive Symptoms

Journal of Psychoactive Drugs April 20, 2021 M. Earleywine, Brianna R. Altman, Joseph A. de Leo 8 citations

ABSTRACT Ketamine, a novel treatment for depression, has generated considerable interest and research. Few experiments address lay impressions of the credibility of ketamine treatment relative to another popular intervention for depression, CBT. Over 500 participants with depressive symptoms read descriptions of CBT, ketamine, and a treatment that combined the two. Descriptions included pros...

DOI: 10.1080/02791072.2021.1912863

Trends in the Top-Cited Articles on Classic Psychedelics

Journal of Psychoactive Drugs February 3, 2021 Bhanu Sharma, David W. Lawrence, Roland R. Griffiths et al. 37 citations

This study was designed to identify trends in the top-cited classic psychedelic publications. The top 50 publications on classic psychedelics with the greatest total of number of citations and annual citation rate were identified and pooled. Unique articles (n = 76) were dichotomized by median year of publication (2010.5); the differential distribution of study characteristics between the...

DOI: 10.1080/02791072.2021.1874573 Psilocybin Cohort study

Traditional Use of Banisteriopsis caapi Alone and Its Application in a Context of Drug Addiction Therapy.

Journal of Psychoactive Drugs 2021 Matteo Politi, Fabio Friso, Gary Saucedo et al. 18 citations

Takiwasi is a therapeutic community for the treatment of Substance Use Disorders (SUDs) that combines traditional Amazonian medicine (TAM) with modern psychotherapy. One of the plant medicines from TAM used in this protocol is purgahuasca. It is a decoction of the vine Banisteriopsis caapi alone, whose use is traditional among the Awajún and other ethnic groups in Peru. The research began with...

DOI: 10.1080/02791072.2020.1820641 Full text Ayahuasca Awajún medicine Banisteriopsis caapi Purgahuasca +1

The ritual use of ayahuasca during treatment of severe physical illnesses: a qualitative study

Journal of Psychoactive Drugs December 7, 2020 Lucas Oliveira Maia, Dimitri Daldegan-Bueno, Luís Fernando Tófoli 33 citations

Diseases that threaten life raise existential questions that can be a source of psychological distress. Studies with psychedelics demonstrate therapeutic effects for anxiety and depression associated with life-threatening illnesses. Ayahuasca has been proposed as a possible therapeutic agent in the treatment of psychiatric disorders. Preliminary studies suggest that ayahuasca could promote...

DOI: 10.1080/02791072.2020.1854399 Ayahuasca Anxiety Thematic analysis Qualitative research +8

Persistent Tinnitus after Inhaled N,N-dimethyltryptamine (DMT)

Journal of Psychoactive Drugs November 26, 2020 Heba Diab, Benjamin Malcolm 1 citation

This case report describes a 39-year-old male with remote history of polysubstance use disorder and depression who developed tinnitus after use of inhaled N,N-dimethyltryptamine (DMT). Although development of ear ringing was attributed to use on a single occasion, tinnitus occurred within the context of a larger self-experiment involving weekly microdoses of lysergic acid diethylamide (LSD)....

DOI: 10.1080/02791072.2020.1847366 Psilocybin Anxiety Tinnitus Hyperacusis +6

Long-term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-containing Mushrooms

Journal of Psychoactive Drugs November 22, 2020 Agustín Lugo-Radillo, Jorge Luis Cortés-lópez 34 citations

Obsessive Compulsive Disorder (OCD) is a chronic neuropsychiatric condition, characterized by obsessions and compulsions, which is usually disabling for the suffering individual. The first-line treatment is not effective in all patients. There is evidence showing the effectiveness of psilocybin and psilocybin-containing mushrooms in the treatment of OCD symptoms. We present the case of a male...

DOI: 10.1080/02791072.2020.1849879 Psilocybin Hallucinogen Obsessive compulsive Psychoactive substance

Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin

Journal of Psychoactive Drugs September 15, 2020 Tracey Varker, Loretta Watson, Kari Gibson et al. 57 citations

The aim of this systematic review was to examine the efficacy of MDMA, ketamine, LSD, and psilocybin for the treatment of posttraumatic stress disorder (PTSD). A search of four databases for English language, peer-reviewed literature published from inception to 18th October 2019 yielded 2,959 records, 34 of which were screened on full-text. Observational studies and RCTs which tested the...

DOI: 10.1080/02791072.2020.1817639 Psilocybin MDMA Ketamine Hallucinogen +3

Chemical Composition of Traditional and Analog Ayahuasca

Journal of Psychoactive Drugs September 8, 2020 Helle Kaasik, Rita C. Z. Souza, Flávia Da Silva Zandonadi et al. 54 citations

Traditional ayahuasca can be defined as a brew made from Amazonian vine Banisteriopsis caapi and Amazonian admixture plants. Ayahuasca is used by indigenous groups in Amazonia, as a sacrament in syncretic Brazilian religions, and in healing and spiritual ceremonies internationally. The study aimed to determine concentrations of the main bio- and psychoactive components of ayahuasca used in...

DOI: 10.1080/02791072.2020.1815911 Ayahuasca Peganum harmala Harmaline Harmine +2

Pilot Evaluation of a Residential Drug Addiction Treatment Combining Traditional Amazonian Medicine, Ayahuasca and Psychotherapy on Depression and Anxiety

Journal of Psychoactive Drugs August 4, 2020 Cecile Giovannetti, Sara García Arce, Brian Rush et al. 55 citations

Recent research highlighted the therapeutic potential of ayahuasca, a psychoactive plant brew used ritually in traditional Amazonian medicine (TAM). The present study evaluates the impact of integrating ayahuasca and TAM with psychotherapy on depression and anxiety in an inpatient addiction treatment program. Male patients (N = 31) were evaluated pre and post treatment using the Beck Anxiety...

DOI: 10.1080/02791072.2020.1789247 Ayahuasca Addiction Beck anxiety inventory Depression economics +4

A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy

Journal of Psychoactive Drugs June 12, 2020 Jason B. Luoma, Christina Chwyl, Geoff J. Bathje et al. 206 citations

After a two-decade hiatus in which research on psychedelics was essentially halted, placebo-controlled clinical trials of psychedelic-assisted therapy for mental health conditions have begun to be published. We identified nine randomized, placebo-controlled clinical trials of psychedelic-assisted therapy published since 1994. Studies examined psilocybin, LSD (lysergic acid diethylamide),...

DOI: 10.1080/02791072.2020.1769878 Full text Psilocybin Anxiety Placebo Hallucinogen +3

Can Psychedelics Alleviate Symptoms of Cluster Headache and Accompanying Mental Health Problems? A Case Report Involving Hawaiian Baby Woodrose

Journal of Psychoactive Drugs May 7, 2020 Shevaugn Johnson, Q. C. Black

ABSTRACT Preliminary evidence supports the efficacy of psychedelics in the alleviation of cluster headache and mental health problems. We describe a case of an individual with cluster headache and mood disorder who claims to have benefited from her use of psychedelics. A forty-eight-year-old woman was referred to a private Australian mental health clinic for the management of chronic pain and...

DOI: 10.1080/02791072.2020.1762023

Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects

Journal of Psychoactive Drugs March 9, 2020 Rafael Lancelotta, Alan K. Davis 32 citations

5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a potent, fast-acting psychedelic. Anecdotal reports from 5-MeO-DMT users suggest that they employ a variety of benefit enhancement (BE) strategies aimed to increase positive effects and decrease any potential challenging effects of the substance, but no empirical study has investigated this claim. We examined the prevalence of BE strategy use...

DOI: 10.1080/02791072.2020.1737763 Full text Mysticism Meaning existential Clinical psychology Psychotherapist +1

Psychedelic Microdosing: Prevalence and Subjective Effects

Journal of Psychoactive Drugs January 23, 2020 Lindsay P. Cameron, Angela Nazarian, David E. Olson 112 citations

Anecdotal reports suggest that the administration of sub-hallucinogenic doses of psychedelic compounds on a chronic, intermittent schedule – a practice known as psychedelic microdosing – is becoming increasingly popular among young adults due to its purported ability to reduce symptoms of depression and anxiety while improving cognitive function and promoting social interaction. Using an...

DOI: 10.1080/02791072.2020.1718250 Full text Traditional medicine

Ayahuasca Users in Estonia: Ceremonial Practices, Subjective Long-Term Effects, Mental Health, and Quality of Life.

Journal of Psychoactive Drugs 2020 Helle Kaasik, Kairi Kreegipuu 31 citations

The study aims to describe ayahuasca users in Estonia and compare their mental health and quality of life to those of nonusers. Ceremonial practices, motivation for ayahuasca use, use-related experiences, and subjective consequences of use are described. We conducted a cross-sectional case-controlled study of thirty ayahuasca users and thirty nonusers matched by gender, age, and education. The...

DOI: 10.1080/02791072.2020.1748773 Full text Ayahuasca Ceremony Mental health Neoshamanism +2

Personality Traits in Former Spanish Substance Users Recovered with Ayahuasca.

Journal of Psychoactive Drugs 2020 Ismael Eduardo Apud Peláez 22 citations

Ayahuasca is a psychoactive brew that contains N,N-dimethyltryptamine and monoamine oxidase-inhibiting alkaloids. It is originally from the Amazon rainforest, but since the 1990s it has expanded worldwide. The compound is used in different religious, spiritual, and therapeutic settings. One of its common applications is for the treatment of addiction. The current study is an assessment of the...

DOI: 10.1080/02791072.2020.1752960 Full text Ayahuasca Spain Addiction treatment Personality +1

The Viability of Microdosing Psychedelics as a Strategy to Enhance Cognition and Well-being - An Early Review.

Journal of Psychoactive Drugs 2020 Joel Bornemann

Psychedelic substances are currently experiencing a renaissance in interest for both therapeutic as well as recreational applications. It has been proposed that microdosing, i.e., ingesting sub-perceptual doses of a psychedelic, could confer some of the benefits of these substances to users while minimizing the risks associated with full-dose use. This review aimed to summarize and examine the...

DOI: 10.1080/02791072.2020.1761573 Full text Microdosing Cognitive enhancements Psychedelics Well-being

Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland.

Journal of Psychoactive Drugs 2020 Samuli Kangaslampi, Aino Hausen, Tarina Rauteenmaa

Despite their acutely inebriating and sometimes unpleasant effects, some people report positive changes in life satisfaction, well-being, or mental health after taking psychedelic drugs. One explanation may be the ability of psychedelics to trigger mystical-type experiences. We examined the validity, reliability, and factor structure of a novel Finnish translation of the Revised Mystical...

DOI: 10.1080/02791072.2020.1767321 Full text LSD Mystical experience Psilocybin Psychedelics +1

Psychedelic Microdosing: A Subreddit Analysis

Journal of Psychoactive Drugs October 24, 2019 Toby Lea, Nicole Amada, Henrik Jungaberle 121 citations

Self-administration of very low doses of psychedelic drugs to improve mental health and wellbeing and enhance cognitive function, known as microdosing, has received recent media attention, but little research has been conducted. We conducted a content analysis of discussions about microdosing from the online forum Reddit. We examined motivations, dosing practices, and perceived benefits and...

DOI: 10.1080/02791072.2019.1683260 Pharmacology

Ayahuasca’s Antidepressant Effects Covary with Behavioral Activation as Well as Mindfulness

Journal of Psychoactive Drugs September 30, 2019 Maha N. Mian, Brianna R. Altman, Mitch Earleywine 47 citations

Ayahuasca, a plant-based hallucinogen that serves as a spiritual medicine in South America, has improved depression in at least one placebo-controlled clinical trial. Case studies suggest that dramatic behavioral changes often follow the Ayahuasca ceremony, but most explanations of antidepressant effects focus on changes in mindfulness. This study investigated whether both mindfulness and...

DOI: 10.1080/02791072.2019.1674428 Mindfulness Ayahuasca Anxiety Behavioral activation +8

Aversiveness and Meaningfulness of Uncomfortable Experiences with Edible Cannabis

Journal of Psychoactive Drugs July 29, 2019 Stacey Farmer, Melissa N. Slavin, Mallory Loflin et al. 16 citations

Cannabis remains the most frequently used illicit drug in the United States. As its legal status has changed, more people have turned to oral administration (“edibles”). 172 individuals who reported an uncomfortable experience with edible cannabis completed an online survey. Despite the aversive nature of the experience, 62.9% of the sample reported that the edible experience was at least...

DOI: 10.1080/02791072.2019.1645371 Full text Cannabis Legalization Clinical psychology

Dimethyltryptamine: Endogenous Role and Therapeutic Potential

Journal of Psychoactive Drugs April 25, 2019 Alexandra Vsl Rodrigues, Francisco Almeida, Maria Augusta Vieira‐coelho 30 citations

N, N-dimethyltryptamine (DMT) is an indole alkaloid produced by a number of plants and animals, including humans. Its psychoactive effects were first described in 1956 by Stephen Szára, but have been exploited for centuries by South American indigenous populations in the form of ayahuasca. In the present review, we assess the state of the art regarding a putative role for endogenous DMT and...

DOI: 10.1080/02791072.2019.1602291 Ayahuasca Anxiety Hallucinogen Depression economics +1

Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy

Journal of Psychoactive Drugs March 15, 2019 Jennifer Dore, Brent Turnipseed, Shannon Dwyer et al. 207 citations

Currently, ketamine is the only legal psychedelic medicine available to mental health providers for the treatment of emotional suffering. Over the past several years, ketamine has come into psychiatric use as an intervention for treatment resistant depression (TRD), administered intravenously without a psychotherapeutic component. In these settings, ketamine's psychedelic effects are viewed as...

DOI: 10.1080/02791072.2019.1587556

Papers